

# PROVIDER Update



CONTRACTUAL | OCTOBER 1, 2024 | UPDATE 24-1058 | 5 PAGES

## New: 3rd Quarter 2024 Injectable Medication HCPCS/DOFR Crosswalk

### Use the updates for dates of service on and after December 6, 2024

The Health Net\* Pharmacy Advisory Committee approved updates to the Injectable Medication Healthcare Common Procedure Coding System (HCPCS)/Division of Financial Responsibility (DOFR) Crosswalk. The Pharmacy Advisory Committee members include physicians and pharmacists.

The approved updates, effective December 6, 2024, are listed on pages 2-5 of this update. Injectable medications are placed in DOFR categories that mirror the DOFR matrix categories in the Health Net\* and Community Health Plan of Imperial Valley *Provider Participation Agreement (PPA)*.

The update includes:

- 22 new injectable medications to be added to the DOFR crosswalk.
- 14 updates and changes to injectable medication procedure codes.
- 1 updated category.
- 8 updates for new generic drugs.

#### Additional Information

Relevant sections of the provider operations manuals have been revised to reflect the information contained in this update as applicable. Provider operations manuals are available electronically in the Provider Library on the provider portal at [provider.healthnetcalifornia.com](http://provider.healthnetcalifornia.com) > Provider Library under Quick Links, or go directly to [providerlibrary.healthnetcalifornia.com](http://providerlibrary.healthnetcalifornia.com).

Providers are encouraged to access the provider portal at [provider.healthnetcalifornia.com](http://provider.healthnetcalifornia.com) for real-time information, including eligibility verification, claims status, prior authorization status, plan summaries, and more.

If you have questions regarding the information contained in this update, contact Community Health Plan of Imperial Valley at 833-236-4141.

#### THIS UPDATE APPLIES TO:

- Participating Physician Groups

#### PROVIDER SERVICES

CHPIV Medi-Cal  
(including ECM and CS providers) –  
833-236-4141

#### PROVIDER PORTAL

[provider.healthnetcalifornia.com](http://provider.healthnetcalifornia.com)

## Additions to injectable medication HCPCS/DOFR crosswalk

The following medications have been approved as additions to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table.

### New drugs

HCPCS	Drug name	Generic name	Primary category	Secondary category
J9999	Anktiva®	Nogapendekin alfa inbakicept-pmln solution for intravesical use	Therapeutic injection	
J3590	Avzivi®	Bevacizumab-tnjn	Therapeutic injection	Chemotherapy <sup>1</sup>
J3590	Beqvez™	Fidanacogene elaparvovec-dzkt injection for intravenous infusion	Therapeutic injection	
J3590	Capvaxive™	Pneumococcal 21-valent Conjugate Vaccine Injection for intramuscular use	Therapeutic injection	Immunization
J0911	Defencath®	Heparin-taurolidine lock flush solution	Therapeutic injection	
J7799	Empaveli®	Pegcetacoplan injection for subcutaneous use NDC 73606-0010-01	Self-injectable	
J7355	iDose® TR	Injection, travoprost, intracameral implant, 1 mcg	Therapeutic injection	
J3590	Imdelltra™	Tarlatamab-dlle for injection for intravenous use	Therapeutic injection	Chemotherapy <sup>1</sup>
J0175	Kisunla™	Donanemab-azbt IV solution 350 mg/20 ml (17.5 mg/ml)	Therapeutic injection	
J3394	Lyfgenia®	Lovotibeglogene autotemcel suspension for intravenous infusion	Therapeutic injection	
J3590	Lynmeldy™	Atidarsagene autotemcel IV suspension	Therapeutic injection	
90683	mResvia™	RSV mRNA PreF vaccine IM suspension PreF syringe 50 mcg/0.5ml	Therapeutic injection	Immunization
J0211	Nithiodote™	Injection, sodium nitrite 3 mg and sodium thiosulfate 125 mg	Therapeutic injection	
J3590	Pyzchiva®	Ustekinumab-ttwe is biosimilar <sup>1</sup> to STELARA (ustekinumab)	Self-injectable	
Q0224	Pemgarda™	Pemivibart IV solution 500 mg/4 ml (125 mg/ml)	Therapeutic injection	
J9999	Rytelo™	Imetelstat sodium for IV solution	Therapeutic injection	Chemotherapy <sup>1</sup>

**New drugs, continued**

<b>HCPCS</b>	<b>Drug name</b>	<b>Generic name</b>	<b>Primary category</b>	<b>Secondary category</b>
<b>J3590</b>	Ryzneuta®	Injection, efbemalenograstim alfa-vuxw, 0.5 mg	Therapeutic injection	
<b>J3590</b>	Selarsdi™	ustekinumab-aekn is biosimilar to Stelara®	Self-injectable	
<b>J3590</b>	Simlandi®	Adalimumab-ryvk auto-injector kit 40 mg/0.4ml biosimilar to Humira®	Self-injectable	
<b>J3590</b>	Tevimbra®	Tislelizumab-jsgr injection for intravenous use	Therapeutic injection	
<b>Q5137</b>	Wezlana™	Injection, ustekinumab-auub, biosimilar to Stelara®, subcutaneous, 1 mg	Self-injectable	
<b>Q5138</b>	Wezlana™	Injection, ustekinumab-auub , biosimilar to Stelara®, intravenous, 1 mg	Therapeutic injection	

**Updates/changes to injectable medication procedure codes or medications**

Updates to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table are based on changes or updates to HCPCS codes or changes in medication descriptions or availability. The following are changes to injectable medications currently listed in the crosswalk.

<b>HCPCS</b>	<b>Drug name</b>	<b>Generic name</b>	<b>Comment</b>
<b>J7171</b>	Adzyna®	Adamts13 recombinant-krhn	Replaces J3590
<b>J3247</b>	Cosentyx®	Injection, secukinumab, IV, 1 mg	Replaces J3590
<b>J1050</b>	Depo-Subq Provera 104®	Medroxyprogesterone acetate Injection	Replaces J3490
<b>91320</b>	Comirnaty® 2024-2025	COVID-19 Vaccine, mRNA, 24-25 formula	2024-2025 formula
<b>91319</b>	Pfizer- BioNTech COVID-19 vaccine/five -11 years of age	COVID-19 mRNA vaccine Tris-S ages five -11 Pfizer immunization suspension 2024-2025 Formula	2024-2025 formula
<b>91318</b>	Pfizer- BioNTech COVID-19 vaccine/six months to four Years of age	COVID-19 mRNA Vaccine Tris-S ages 6 months-4 years of age Pfizer IM Susp 2024-2025 Formula	2024-2025 formula
<b>J3263</b>	Loqtorzi®	Toripalimab-tpzi, 1 mg	Replaces J9999
<b>J2267</b>	Omvoh™	Mirikizumab-mrkz, 1 mg Injection	Replaces J3590
<b>J9309</b>	Polivy®	Polatuzumab vedotin-piiq for Intravenous use	Replaces J3590
<b>J1203</b>	Pombiliti™	Cipaglucosidase alfa-atga for IV solution	Replaces J3590

## Updates/changes to injectable medication procedure codes or medications, *continued*

HCPCS	Drug name	Generic name	Comment
<b>J1744</b>	Sajazir™	Icatibant acetate subcutaneous solution pre-filled syringe	New generic
<b>J2919</b>	Solu-Medrol®	Methylprednisolone sodium succinate for injection PF 500	Replaces J2920 and J2930
<b>J1748</b>	Zymfentra®	Infliximab-dyyb) injection for subcutaneous use-Celltrion USA	Replaces J3590
<b>J3393</b>	Zynteglo™	Betibeglogene autotemcel	Replaces J3590

### Category changes

The following medications has been approved to correct the secondary category listed below.

HCPCS	Drug name	Generic name	Primary category	Secondary category
<b>J3590</b>	Adbry™	Tralokinumab-ldrm injection for subcutaneous use	Self-injectable	

### New generic injectable medications

The following medications have been approved as additions to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table.

HCPCS	Drug name	Generic name	Primary category	Secondary category
<b>J2246</b>	Micafungin	Injection, micafungin in sodium (Baxter), not therapeutically equivalent to J2248, 1 mg	Therapeutic injection	Home health/ Infusion <sup>2</sup>
<b>J1598</b>	Glycopyrrol	Injection, glycopyrrolate (fresenius kabi), not therapeutically equivalent to J1596, 0.1 mg	Therapeutic injection	
<b>J2183</b>	Merrem	injection, meropenem (wg critical care), not therapeutically equivalent to J2185, 100 mg	Therapeutic injection	Home health/ Infusion <sup>2</sup>
<b>J2468</b>	Palonosetron	Injection, palonosetron hydrochloride (avyxa), not therapeutically equivalent to J2469, 25 mcg	Therapeutic injection	Chemotherapy adjunctive <sup>1</sup>
<b>J2373</b>	Immphentiv	Injection, phenylephrine hydrochloride, 20 mcg	Therapeutic injection	

---

**New generic injectable medications, *continued***

<b>HCPCS</b>	<b>Drug name</b>	<b>Generic name</b>	<b>Primary category</b>	<b>Secondary category</b>
<b>J9075</b>	Cyclophosphamide	Injection, cyclophosphamide, 5 mg, not otherwise specified	Therapeutic injection	Chemotherapy <sup>1</sup>
<b>J0872</b>	Daptomycin for Injection (room temperature)	Injection, daptomycin, unrefrigerated, not therapeutically equivalent to J0878 or J0873, 1 mg, Xellia	Therapeutic injection	Home health/ Infusion <sup>2</sup>
<b>J9258</b>	Abraxane®	Paclitaxel protein-bound particles for injectable suspension (albumin-bound). Manufacture by Teva	Therapeutic injection	Chemotherapy <sup>1</sup>

HCPCS codes were taken from the Centers for Medicare & Medicaid Services HCPCS website at [www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/Alpha-Numeric-HCPCS.html](http://www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/Alpha-Numeric-HCPCS.html).

<sup>1</sup>If associated with a cancer diagnosis – ICD-10 codes between C00.0-C79.9, C7A.00-C7B.8, C80.0-C96.9, D00.0-D09.9.

<sup>2</sup>When administered by a nurse in a home setting.